NEW YORK – Genentech on Wednesday began a Phase III trial of its PD-L1 inhibitor atezolizumab (Tecentriq) in bladder cancer using Natera's molecular residual disease (MRD) test Signatera as a companion diagnostic.
NEW YORK – Genentech on Wednesday began a Phase III trial of its PD-L1 inhibitor atezolizumab (Tecentriq) in bladder cancer using Natera's molecular residual disease (MRD) test Signatera as a companion diagnostic.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.